University of Michigan

Xiaoqin Li

Duxin Sun

Shaomeng Wang

Liu Liu

Longchuan Bai

Jolanta Grembecka

Tomasz Cierpicki

Donna McEachern

Dmitry Borkin

Jay L Hess

Chao-Yie Yang

Angelo Aguilar

Jeanne Stuckey

Jennifer Lynn Meagher

Jianfang Chen

Arul M Chinnaiyan

Bing Zhou

Yujun Zhao

Irfan A Asangani

Hacer Karatas

Ruijuan Luo

Xu Ran

Kevin Lloyd Greenman

Mohamed Ibrahim

Haibin Zhou

Artem Plekhov

Donna McEachem

Donna Mceacherm

Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.

BET bromodomain inhibitors and therapeutic methods using the same

The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 3: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.

Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 4b: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.

The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 2: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.

Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed.

Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same

The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 4: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.

BCL-2/BCL-XL inhibitors and therapeutic methods using the same

Growing community of inventors

Ann Arbor, MI, United States of America

Xiaoqin Li